Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00451074
Status:
COMPLETED
Last Update Posted:
2012-03-23
First Post:
2007-03-21
Brief Title:
Six Month Study of Gentamicin in Duchenne Muscular Dystrophy With Stop Codons
Sponsor:
Nationwide Childrens Hospital
Organization:
Nationwide Childrens Hospital
Study Overview
Official Title:
A Six Month Randomized Clinical Trial of Gentamicin in Duchenne Muscular Dystrophy Subjects With Stop Codon Mutations
Status:
COMPLETED
Status Verified Date:
2012-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the safety of giving intravenous IV gentamicin to boys with Duchenne muscular dystrophy who have stop codon mutations
Detailed Description:
The primary purpose of this second cohort is to see if the IV Medication gentamicin is safe to give twice a week for six months to boys with Duchenne muscular dystrophy DMD Secondarily we want to know if gentamicin can help strengthen the muscles of boys with DMD who have a particular type of genetic mutation known as a stop codon The gentamicin is thought to allow for read-through of this type of mutation which would allow for the production of dystrophin a protein which is lacking in boys with DMD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 7R01NS043186 | NIH | None | httpsreporternihgovquickSearch7R01NS043186 |